A research team at the Center for Neuroscience Imaging Research (CNIR) within the Institute for Basic Science (IBS), together ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...
On 9 December 2025, Relation Therapeutics announced a multi-program collaboration with Novartis, securing US$55 million in ...
Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication ...
Chonnam National University has once again solidified its international reputation as Korea's leading institution in "nano-regenerative medicine" ...
Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation November 26, 2025 9:00 ...
Daniel Ives You can reverse the age of cells all the way down to zero in just a few weeks. So you can actually take a ...
An in-depth look at how Turkey’s top clinics use next-generation technology to deliver superior results at globally ...
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback